You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

16 search results for: IL-13

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and <b>IL-13</b>

expert video

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

24 min

Pulmonology

Dr. Reynold Panettieri discusses how IL-4 and IL-13 drive airway remodeling in type 2 asthma.

Can targeting IL-4 and <b>IL-13</b> have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?

expert video

Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?

5 min

Dermatology

Dr. Amy Paller discusses how targeting IL-4 and IL-13 can improve burden of AD.

What role does IL-4 and <b>IL-13</b> have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

expert video

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

5 min

Dermatology

Dr. Oscar Palomares explains that IL-4 and IL-13 are crucial cytokines in type 2 inflammation, playing both unique and overlapping roles, including T cell expansion and contributing to clinical symptoms in chronic diseases.

Normalizing Skin Barrier by Inhibiting IL-4 & <b>IL-13</b>, or <b>IL-13</b> Alone

expert video

Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone

5 min

Dermatology

Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrier dysfunction, and neuroimmune dysregulation

expert video

What Drives PN Disease? Exploring the Complexity of PN Pathophysiology

15 min

Dermatology

Dr. Brian Kim discusses the numerous contributors to PN pathophysiology, including type 2 inflammation, neuronal dysfunction, and dermal fibrosis, emphasizing the unique and overlapping roles of IL 31, IL-4 and IL-13 in its pathology.

expert video

Barrier disruption in AD and the development of environmental and food allergies

5 min

Dermatology

Dr. Casale discusses the critical role of barrier disruption in atopic dermatitis

expert video

Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD

20 min

Dermatology

This video features Dr. Eric Simpson's presentation on the importance of achieving disease control in adults with moderate-to-severe AD. Dr. Simpson discusses how adult patients and HCPs talk about disease control and the tools available to help define it. He also explores the roles of IL-4 and IL-13 in the pathophysiology of AD, including how both cytokines promote inflammation and, in turn, contribute to the cumulative burden of the disease. The video concludes with a brief panel discussion.

Infographic

FeNO: A Biomarker of Type 2 Inflammation in Pediatric Asthma Patients

5 min

Pulmonology

Learn about the role of FeNO as a noninvasive test to identify type 2 inflammation in pediatric patients with asthma

expert video

Role of Type 2 Cytokines in Asthma and COPD

2 min

Type 2 Inflammation

Dr Mario Castro explains how type 2 cytokines play a crucial role in airway remodeling and inflammation in asthma and COPD, impacting patient outcomes.

Infographic

Type 2 Inflammation Underpins Pediatric Severe Asthma

5 min

Pulmonology

Learn about the role type 2 inflammation plays in the burden and pathophysiology of severe asthma in pediatric patients.

videoanimation

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

5 min

Dermatology

Learn more about how chronic and systemic type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis

interactivity

The Cycle of Inflammation in Adult Asthma

5 min

Pulmonology

Explore the role of chronic type 2 inflammation in the cycle of exacerbations and worsening lung function in asthma patients

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: IsraelChange country/region